121 results about "Insulin sensitivity" patented technology

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present application relates to the technical field of reversing insulin resistance, and particularly relates to a composition with components for reversing insulin resistance and a preparation method thereof, the composition comprising quercetin, procyanidin, malic acid, magnesium carbonate, zinc lactate and grains, and through synergistic effects of the components, the composition can reduce fasting blood glucose, fasting insulin and insulin resistance index, and improve insulin sensitivity index, and overcomes the problems in the prior art that the components of the traditional Chinese medicine composition are complex, the effective components for reversing insulin resistance and the synergistic mechanism are not clear, and the content of the effective components in the same medicine is not consistent due to the influence of the growth environment, resulting in unpredictable treatment effect.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

The invention provides a method for detecting insulin sensitivity, which comprises the following steps: (1) transfecting a cell to be detected by using a GLUT4myc cDNA plasmid: transfecting the cell to be detected by using the GLUT4myc cDNA plasmid, so that the cell stably expresses GLUT4myc; (2) measuring the endocytosis rate of the GLUT4myc: performing endocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody to be endocytosed, and regularly detecting the amount of the GLUT4myc combined with the anti-myc antibody remained on the surface of the cell; (3) measuring the GLUT4myc exocytosis rate: performing exocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody in the cell to exocytosis, and regularly detecting the translocation amount of the GLUT4myc combined with the anti-myc antibody in the cell to the surface of the cell; (4) calculating the difference value between the GLUT4myc exocytosis rate and the GLUT4myc endocytosis rate, and calculating the insulin sensitivity according to the difference value; the insulin sensitivity evaluation method has the beneficial effects that the insulin sensitivity is evaluated by detecting the exocytosis and endocytosis rates of fat cells, muscle cells or peripheral blood lymphocytes GLUT4, so that early-stage diabetic patients can be identified, and the pathogenesis of diabetes mellitus can be researched.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

A method of determining an insulin bolus to be administered by an insulin delivering device is disclosed. According to the inventive method, glucose measurement data corresponding to glucose level measurement signals detected by a continuous glucose sensor are received. An insulin bolus to be administered by the insulin delivering device is determined based on a formula having expressions indicative of, for example, glucose level derived from the glucose measurement data, carbohydrate-to-insulin ratio (CIR) and an insulin sensitivity factor (ISF). The method can be carried out using a processor of a device such as insulin pen, an insulin pump, a remote control device configured to remotely control an insulin pump or an insulin pen, a continuous glucose meter, a controller of a continuous glucose meter, a blood glucose meter, and a portable electronic device such as a smart phone, smart watch or tablet.

The invention aims to provide a peptide for accelerating fat metabolism and application thereof, the peptide is prepared into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through peptide library screening, bioinformatics analysis screening and fat cell decomposition experiment verification, and it is verified that the active peptide obtained through screening has the effects of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content and reducing body weight; the insulin sensitivity and the glucose tolerance are improved, and the prevention and treatment effects on obesity and complications thereof are realized.

The application aims to provide a peptide for accelerating fat metabolism and application thereof, and to prepare the peptide into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through screening of a peptide library, screening through bioinformatics analysis, and verification through fat cell decomposition experiment, and the application verifies that the active peptide screened has the effect of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content, reducing body weight, improving insulin sensitivity and glucose tolerance, and realizing the prevention and treatment effect on obesity and its complications.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

The invention relates to a gestational blood glucose data grouping method and a server. The method comprises the following steps: acquiring blood glucose data of a gestational user and input basic information; based on a preset group division rule, the gestational user data is divided into a plurality of subgroups, and the group division rule is determined based on the difference and difference of influence trends of various hormones on insulin resistance or insulin sensitivity, so that different-direction associated subgroups and / or same-direction associated subgroups are obtained; a shared database is constructed, data information in all subgroups is stored in the form of multi-dimensional blood glucose comprehensive evaluation indexes, and the multi-dimensional blood glucose comprehensive evaluation indexes are obtained through calculation based on the average blood glucose index related to blood glucose, the blood glucose fluctuation factor, the postprandial peak gradient and the night blood glucose load.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The present disclosure provides methods and materials related to MANPs. In one embodiment, the present disclosure provides a method for treating hypertension with metabolic syndrome by administering MANPs to a patient in need of such treatment. In one embodiment, the present disclosure provides a method comprising administering MANPs to a patient to lower blood pressure (BP). In one embodiment, the method of the present disclosure is employed to treat patients with low baseline cGMP levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to increase or improve plasma cGMP levels, plasma ANP-like peptide levels, insulin sensitivity, or plasma NEFA levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to lower plasma glucose levels.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a strain of lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy and application of the lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy. The preservation number of the plant lactobacillus is CGMCC (China General Microbiological Culture Collection Center) No.31657, and the plant lactobacillus is screened from excrement of healthy infants, has excellent acid resistance and cholate resistance, is high in oxidation resistance and reducing capacity, can effectively control the rise of fasting blood-glucose level of diabetic mice and can enhance the glucose tolerance of the diabetic mice; and the protein also has the capabilities of improving pancreas islet functions and regulating insulin resistance and insulin sensitivity. The strain has a wide application prospect in preparation of drugs for relieving or treating pancreas islet dysfunction and diabetic nephropathy.

The invention relates to the field of biological medicine, and discloses a protein degradation targeting chimera (PROTAC) compound targeting 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) and medical application of the protein degradation targeting chimera (PROTAC) compound. The compound comprises a structural unit shown as a formula I, X is a 11 beta-HSD1 binding ligand, Y is a connecting chain, Z is an E3 ubiquitin ligase ligand, ubiquitination degradation of 11 beta-HSD1 can be induced, and therefore the function of the compound can be regulated and controlled at the protein level. Different from a traditional small-molecule inhibitor, the degradation agent can significantly reduce expression of 11 beta-HSD1 in cells and improve glucocorticoid signal abnormality, and shows a novel action mode at molecular and cellular levels. In diabetes, obesity, lipid metabolism disorder and related complication models, the compound can reduce blood sugar, improve insulin sensitivity, regulate blood fat and relieve inflammation, and shows a good treatment prospect. The half degradation concentration of a representative compound in vitro is about 1000 nM, and feasible degradation efficiency is achieved. The compound can be synthesized by Click chemistry and other methods, and can be prepared into a pharmaceutical composition for prevention and treatment of type II diabetes, metabolic syndrome, polycystic ovarian syndrome and other diseases, and a new strategy is provided for research and development of related drugs.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention belongs to the field of biological medicines, and relates to application of isohesperidin or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating obesity or related metabolic syndromes thereof. The invention finds that the natural compound isohesperidin can obviously induce adipocyte browning and improve the expression level and the cell oxygen consumption rate of uncoupling protein 1, so that the weight gain is effectively inhibited and the glucose homeostasis and the insulin sensitivity are improved in an obesity mouse model, and meanwhile, the isohesperidin can be used for inhibiting the adipocyte browning. No obvious cytotoxicity and animal toxicity are observed in an effective dose of isohesperidin, so that the isohesperidin has better safety and is expected to be used for preventing and / or treating obesity or related metabolic syndromes thereof.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

The invention discloses an FSTL1 overexpression adeno-associated virus and application thereof, and aims to efficiently deliver a mouse source FSTL1 gene into mouse muscle cells by virtue of a virus infection mechanism by utilizing the targeting property of AAV1 type to muscle tissues. FSTL1 is overexpressed in mouse muscle tissue, muscle insulin signal transduction and glucose metabolism processes are adjusted from multiple dimensions of insulin signal channel activation, glucose transporter regulation and control and the like, and therefore the insulin sensitivity and glucose metabolism conditions of muscles in an obese mouse model are improved.

The present invention relates to compounds which are for use in the treatment, alleviation or prevention of obesity and / or a disease, disorder or abnormality associated therewith. In a further embodiment, the compounds are for use in reducing neuroinflammation, reducing microgliosis, and / or improving insulin sensitivity, preferably in an obese subject. In another embodiment, the compounds are for use in the treatment, alleviation or prevention of a disease, disorder or abnormality which is responsive to the modulation of IL-17A and / or IL36G. The compounds are NLRP3 inflammasome pathway inhibitors. In particular, the compounds inhibit the activation of a component of the NLRP3 inflammasome pathway. More particularly, the component of the inflammasome pathway is NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, in particular IL-1 beta and / or IL-18 levels are modulated thereby.

A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.

Provided herein are compositions, formulations, and methods of treatment for weight loss and satiety improvement for a subject in need thereof, including a human subject in need thereof. The compositions may be used to improve satiety, insulin sensitivity and the microbiome in a subject in need thereof. The composition may further used for weight management and / or in mammals, including humans.

The present invention relates to a bacterial strain of the species Limosilactobacillus mucosae, or a lysate or culture supernatant thereof, for use in the prevention and / or treatment of a disorder requiring increased production of GLP-1 in a subject in need thereof, wherein the disorder is selected from (i) a disorder associated with impaired insulin sensitivity and / or blood glucose regulation, and (ii) a loss of muscle mass and / or loss of muscle function.